Table: Astellas 6-MTH group results (IFRS)

Astellas Pharma

30/10/2025 06:31

Oct 30 (Reuters)- 
              Astellas Pharma Inc. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   6 months ended      6 months ended       Year to 
                  Sep 30, 2025        Sep 30, 2024     Mar 31, 2026 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales             1.03 trln            935.62          2.03 trln  
                   (+10.1 pct)         (+22.0 pct)      (+6.2 pct)  
  Operating          199.38               93.71           240.00    
                  (+112.8 pct)         (+69.9 pct)     (+484.8 pct) 
  Pretax             194.61               89.04           230.00    
                  (+118.6 pct)         (+58.1 pct)     (+636.3 pct) 
  Net                147.64               73.51           180.00    
                  (+100.8 pct)        (+105.3 pct)     (+254.7 pct) 
  EPS Basic         82.44 yen           41.06 yen       100.50 yen  
  EPS Diluted       82.17 yen           40.91 yen                   
  Ann Div                               74.00 yen        78.00 yen  
  -Q2 Div           39.00 yen           37.00 yen                   
  -Q4 Div                               37.00 yen        39.00 yen  
 
  NOTE - Astellas Pharma Inc.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4503.T